Five Antiretroviral Drug Class-Resistant HIV-1 in a Treatment-Naïve Patient Successfully Suppressed with Optimized Antiretroviral Drug Selection

Journal of the International Association of Providers of AIDS Care

Volumn 14, Issue 5, 2015, Pages 398-401

  Volpe, Joseph M ^a   Ward, Douglas J ^b   Napolitano, Laura ^a   Phung, Pham ^a   Toma, Jonathan ^a   Solberg, Owen ^a   Petropoulos, Christos J ^a   Walworth, Charles M ^a  

^a MONOGRAM BIOSCIENCES   (United States)

^b Dupont Circle Physician's Group   (United States)

Author keywords

enfuvirtide; integrase inhibitors; maraviroc; transmitted drug resistance; tropism

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS 1 ANTIBODY; LAMIVUDINE; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS ANTIBODY; ANTIRETROVIRUS AGENT; CYCLOHEXANE DERIVATIVE; ENFUVIRTIDE; GLYCOPROTEIN GP 41; INTEGRASE INHIBITOR; PEPTIDE FRAGMENT; TRIAZOLE DERIVATIVE;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CONSENSUS SEQUENCE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC50; MALE; PHYLOGENY; PRIORITY JOURNAL; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; WESTERN BLOTTING; ANTIVIRAL RESISTANCE; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; VIRAL TROPISM; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MALE; PEPTIDE FRAGMENTS; TRIAZOLES; VIRAL TROPISM;

EID: 84941954266     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/2325957415596229     Document Type: Article

References (15)

1. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999; 282 (12): 1135-1141.
2. Kim D, Wheeler W, Ziebell R, et al. Prevalence of transmitted antiretroviral drug resistance among newly-diagnosed HIV-1-infected persons, US. In: 17th CROI 2010, San Francisco, CA, February 16-19, 2010. Abstract # 580; 2007.
3. Ocfemia MC, Kim D, Ziebell R, et al. Prevalence of transmitted HIV drug resistance in US. In: 19th CROI 2012, Seattle, WA, March 5-9, 2012. Abstract #730; 2006-2009.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Web site. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Published May 1, 2014. Updated April 8, 2015. Accessed May 2, 2014.
5. Young B, Fransen S, Greenberg K, et al. Transmission of integrase strand-transfer inhibitor multi-drug resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy. Antivir Ther. 2011; 16 (2): 253-256.
6. Boyd SD, Maldarelli F, Sereti I, et al. Transmitted raltegravir resistance in an HIV-1 CRF-AG-infected patient. Antivir Ther. 2011; 16 (2): 257-261.
7. Peuchant O, Capdepont S, Ragnaud J, et al. Primary resistance to enfuvirtide (T20) in recently HIV-1 infected antiretroviral-naïve patients from the ANRS Aquitaine cohort. Antivir Ther. 2007; 12 (4): 559-562.
8. Blick G, Kagan RM, Coakley E, et al. The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient. J Infect Dis. 2007; 195 (9): 1250-1259.
9. Langmead B, Salzberg S,. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012; 9 (4): 357-359.
10. Nelson M, Arastéh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005; 40 (4): 404-412.
11. Johnson VA, Calvez V, Günthard HF, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013; 21 (1): 1-14.
12. Satoris MM, Huang W, Petropoulos CJ, Whitcomb JM,. Sensitivity of detection of minority species in a single cycle replication assay is influenced by the biochemical mechanism of resistance: insight into the mechanism of NRTI-resistance and cross-resistance in patient samples. Antivir Ther. 2000; 5 (suppl 3): 2.
13. Schuitemaker H, Wout ABV, Lusso P,. Clinical significance of HIV-1 coreceptor usage. J Trans Med. 2010; 9 (suppl 1): S5.
14. Wilkin TJ, Goetz MB, Leduc R, et al. Tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clin Infec Dis. 2011; 52 (7): 925-928.
15. Hurt CB,. Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule. Antivir Ther. 2011; 16 (2): 137-140.